Recce (ASX:RCE)'s unapproved drug proves successful treatment for life-threatening illness

Company News

by Michael Luu

Superbug and viral pathogen treatment developer Recce Pharmacetical (ASX:RCE)’s unapproved drug R327 has successfully saved a patient suffering a life-threatening illness.

Despite not undertaking clinical trials, nasal treatment R327 was accessible to the individual via Category A of the Therapeutic Goods Administration special access scheme. Recce (ASX:RCE) intends to proceed with clinical trials for the product.

The news has shot Recce’s shares up 5.1 per cent to $1.03

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.